Proclara continuing Phase Ib of AD candidate NPT088

Proclara Biosciences Inc. (Cambridge, Mass.) said an independent DMC recommended continuation of a double-blind, placebo-controlled, U.S. Phase Ib trial evaluating 4 dose levels of 0.6-20 mg/kg IV NPT088 in up to 66 patients with mild to moderate probable Alzheimer’s disease (AD). The recommendation was based on interim safety data showing that once-monthly 0.6 mg/kg NPT088 for 6 months was well tolerated.

The trial's primary endpoint is safety. Secondary endpoints include pharmacokinetics and immunogenicity...